Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valuing Infectious Disease Deals: EBI's new Deal Valuation Tool

This article was originally published in Start Up

Executive Summary

The growing problem of antibiotic resistance has forced big drug companies to take renewed interest in novel anti-infectives. Although the number of deals signed thus far in 2011 in this therapeutic area is lower than in prior years, licensing commitments have remained strong. Different deal structure scenarios based on the recent platform alliance between Sanofi and Rib-X are taken through EBI's new Strategic Transactions Deal Valuation Tool.

You may also be interested in...

Tracking Big Pharma's Appetite For Regional Deals

A review of Big Pharma regional dealmaking in 2006-2010 shows a slower uptick in the number of alliances than the steady year-over-year growth seen from 2001-2006.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts